Tag : multiple sclerosis (ms)

Neurology

Alemtuzumab: Prior Autoimmunity Does Not Predict Adverse Events

Newsemia
There’s no evidence to support the idea that previous autoimmunity before or after alemtuzumab predicts subsequent rare but serious autoimmune events recently linked to the...
Neurology

Safety Concern With Fingolimod to Ocrelizumab Switch in MS

Newsemia
A new study has suggested that some patients who make this switch may experience "double immunosuppression" – very low levels of both T and B...
Neurology

Researchers Identify Five Cognitive Phenotypes in MS

Newsemia
Researchers have identified five cognitive phenotypes among patients with multiple sclerosis, which can help drive tailored rehabilitative strategies, say researchers. Medscape Medical News Source link...
Neurology

Optimal Dose of Fingolimod for Multiple Sclerosis Confirmed

Newsemia
The 0.5-mg dose of fingolimod provides a greater reduction in annualized relapse rate vs both the 0.25-mg dose of fingolimod and the 20-mg dose of...
Neurology

B Cell Test Predicts Alemtuzumab Autoimmunity in MS

Newsemia
Analyzing B cell counts before treatment could help select patients for the drug, a new study suggests. Medscape Medical News Source link...
Neurology

High Plasma GFAP Level Predicts Disability in Progressive MS

Newsemia
A high level of glial fibrillary acidic protein (GFAP) in the blood may predict worsening disability in patients with secondary progressive multiple sclerosis (MS), according...
Neurology

Masitinib Impresses in 'Nonactive' Progressive MS

Newsemia
The drug, with a completely new mechanism of action for multiple sclerosis, slowed disability in nonactive primary and secondary progressive forms of the disease, where...
Neurology

Multiple Sclerosis Prodrome Holds Promise of Earlier Diagnosis

Newsemia
There is now no doubt that a prodromal phase of MS exists for several years before the first demyelinating event occurs, latest evidence shows. Medscape...
Neurology

NfL Blood Biomarker Captures Suboptimal Treatment Response in MS

Newsemia
Measuring levels of neurofilament light chain is an effective way of detecting disease activity and the need to optimize treatment in patients with multiple sclerosis,...
Neurology

App for MS Aims to Capture Elusive Signals of Progression

Newsemia
Investigators in Switzerland are testing an application for smartphones that they hope will elucidate subtle signs of disease progression in multiple sclerosis (MS) — beyond...
Neurology

Lessons for Patients With MS and COVID-19

Newsemia
Two lessons about managing patients with MS and COVID-19 have emerged: Combined PCR and serology helped avoid disease reactivation in asymptomatic carriers during the pandemic...
Neurology

In MS, Serious AEs More Common in Rituximab vs Ocrelizumab

Newsemia
Medscape Medical News Source link...
Neurology

Cardiovascular Risk Factors Linked to Brain Atrophy in MS

Newsemia
Even low levels of exposure to cardiovascular risk factors are important in MS and might affect brain volume loss, a new study suggests. Medscape Medical...
Neurology

Smoking Increases Risk of High Plasma NfL Levels in MS

Newsemia
A study has found that patients with multiple sclerosis who smoke have an increased risk of higher plasma neurofilament light levels (pNfL), which increase disease...
Neurology

Lowering Rituximab Dose in Patients With MS Safe, Effective

Newsemia
A new study has found that reducing rituximab dosage from 1,000 mg every 6 months to 500 mg every 6 months is a safe and...
Neurology

In the Age of Digital Medicine, This Humble Medical Tool Hangs On

Newsemia
The simple reflex hammer has a long, storied past and remains as relevant as ever in the neurology clinic. Medscape Neurology Source link...
Neurology

TNF Inhibitors Linked to Inflammatory CNS Events

Newsemia
Use of tumor necrosis factor inhibitors in patients with autoimmune diseases may increase risk for inflammatory demyelinating and non-demyelinating central nervous system events, new data...
Neurology

FDA OKs Ofatumumab (Kesimpta) for Relapsing Forms of MS

Newsemia
The FDA has approved ofatumumab (Kesimpta) as the first self-administered, targeted B-cell therapy for adults with relapsing forms of multiple sclerosis. FDA Approvals Source link...
Neurology

NIAID Testing Remdesivir Plus MS Drug for COVID-19

Newsemia
The ACTT-3 randomized controlled trial is testing the safety and efficacy remdesivir in combination with the immunomodulator interferon beta-1a in hospitalized COVID-19 patients. Medscape Medical...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World